Up to 41%* superior improvement in lung function vs. Spiolto Respimat (180mL vs. 128mL; $p<0.001$)[1]

*ANORO showed superiority on the primary endpoint of trough FEV_1 compared to Spiolto Respimat (tiotropium/olodaterol 5/5mcg).[1,6] Trough FEV_1 improved to 180mL for ANORO (n=225) versus 128mL for Spiolto Respimat (n=224) over an 8-week treatment period in adults with symptomatic moderate COPD (mMRC ≥2 and post-bronchodilator FEV_1 50–70%); difference 52mL (95% CI: 28, 77; p<0.001) in ITT population.[1]

For symptomatic patients with COPD, increasing lung function and reducing breathlessness has demonstrated a positive effect on their quality of life.[7] ANORO achieved superior lung function improvement and improved symptoms vs. other LAMA/LABAs within the class, helping reduce the impact of COPD on your patients' daily lives.[1,3]

Trough FEV_1 at Week 8 in adults with moderate COPD†[1]



ANORO delivered dose: 55/22mcg
Adapted from Feldman *et al.* 2017

Minimum clinically important difference (MCID) defined as the minimum improvement that patients can perceive. In lung function, MCID=100 mL improvement in trough FEV_1 from baseline.[8]
†Defined as FEV_1 ≤70% to ≥50% predicted, mMRC ≥2.[1]

Anoro is subject to a Special Authority Criteria and is only funded for patients stabilised on a LAMA and who would receive additional benefit from switching to a combination product.[5] Anoro is well tolerated. Common adverse events include nasopharyngitis, cough and oropharyngeal pain.[4]

1. Feldman GJ et al. Adv Ther 2017;34(11):2518–2533. 2. Alcázar Navarrete B et al. Pulm Ther 2018;4:171–183. 3. Maltais F et al. Adv Ther 2019;36:2434–2449. 4. GlaxoSmithKline New Zealand. Anoro Ellipta Data Sheet. GSK NZ; 2020. Available at https://medsafe.govt.nz/profs/datasheet/a/anoroelliptapowder.pdf (Last accessed February 2021). 5. PHARMAC Special Authority for Long-Acting Muscarinic Antagonists with Long-Acting Beta-Adrenoceptor Agonists. Available from https://ieschedule.pharmac.govt.nz/ScheduleOnline.php?osq=Umeclidinium+with+vilanterol (Last accessed February 2021). 6. Spiolto Respimat Data Sheet. Available at https://medsafe.govt.nz/profs/datasheet/s/SpioltoRespimatinh.pdf (Last accessed March 2021). 7. Donohue JF et al. Pulm Pharmacol Ther 2018;49:11–19. 8. Jones PW et al. Am J Respir Crit Care Med 2014; 189:250–255.

LAMA, long-acting muscarinic antagonist; LABA, long-acting β2-agonist; COPD, chronic obstructive pulmonary disease; FEV_1, forced expiratory volume in one second

Anoro Ellipta (umeclidinium bromide/vilanterol trifenatate inhaler 62.5/25mcg per inhalation) is a **Prescription Medicine.** *Anoro Ellipta* is indicated as a long-term maintenance bronchodilator treatment to relieve symptoms in adult patients with Chronic Obstructive Pulmonary Disease (COPD). ***Anoro Ellipta* is a fully funded medicine; Special Authority criteria apply. Maximum Daily Dose:** One inhalation once daily. **Contraindications:** Patients with severe milk-protein allergy or those who have hypersensitivity to umeclidinium, vilanterol or any excipients **Side Effects:** Nasopharyngitis, oropharyngeal pain, sinusitis, pharyngitis, cough, urinary tract infection, constipation, dry mouth, hypertension, upper respiratory tract infections. **Warnings and Precautions:** Not recommended for use in patients with asthma or for relief of acute symptoms or an acute exacerbation. Use care when co-administering with strong CYP3A4 inhibitors (e.g. ketoconazole), beta-blockers and in patients with severe cardiovascular disease, narrow-angle glaucoma or urinary retention. **Pregnancy:** There are insufficient data from the use of umeclidinium/vilanterol in pregnant women. *Anoro Ellipta* should be used during pregnancy only if the expected benefit to the mother justifies the potential risk to the fetus. Before prescribing *Anoro Ellipta*, please review the data sheet for information on dosage, contraindications, precautions, interactions and adverse effects. The data sheet is available at www.medsafe.govt.nz.

Spiolto and *Respimat* are registered trade marks of Boehringer Ingelheim. *Anoro* and *Ellipta* are registered trade marks of the GlaxoSmithKline group of companies. The data sheets are available at www.medafe.govt.nz. *Anoro Ellipta* was developed in collaboration with Innoviva Inc. Marketed by GlaxoSmithKline NZ Limited, Auckland. **Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500. TAPS DA2123AM-PM-NZ-UCV-LBND-200004 Date of approval: Feb 2021.**